Company profile

Crossject

crossject.comHeadquarters: France
51-200 employeesProduct Vendor
Crossject logo

Primary focus

Development of a needle-free, pre-filled, single-use auto-injector platform for rapid administration of emergency medications.

Why it’s included

The company develops and manufactures the ZENEO Midazolam needle-free autoinjector, explicitly funded by BARDA and Project BioShield for nerve agent exposure, meeting the topic's requirements for rapid-onset, field-deployable chemical threat countermeasures.

Relevant capabilities

  • Needle-free pre-filled single-use auto-injector design and development
  • Clinical development for emergency indications
  • Manufacturing and scale-up of pre-filled auto-injector devices
  • Human factors engineering for emergency-use devices
  • Regulatory strategy and support for FDA authorization
Commercial sectorAutoinjectors and Rapid Drug Delivery Devices
Technology classesBenzodiazepine anticonvulsants for nerve-agent seizures, Autoinjector drug delivery devices

Relevant commercial products

  • Needle-free, pre-filled, single-use auto-injector platform
  • ZENEO
  • ZEPIZURE®

Relevant patents

5 families, 5 publications
  • Needleless injection device equipped with a protected reservoir US-8784371-B2
  • Needleless injection device with an angularly-positionable closure stopper US-10799638-B2
  • Needleless injection device with a curved membrane US-11738151-B2
  • Needleless injection device with an improved sealing gasket US-10675409-B2
  • Needleless injection device with sliding membrane US-10653839-B2

← Back to what’s inside this report